Smartlab Europe

Press Releases

Sanofi and WRAIR sign research agreement to co-develop Zika vaccine candidate

Sanofi and its vaccines global business unit Sanofi Pasteur Research and Development Agreement with the Walter Reed Army Institute of Research (WRAIR) on the co-development of a Zika vaccine candidate.    According to the terms of...

FDA Approves Gilead’s Epclusa for the Treatment of All Genotypes of Chronic Hepatitis C

Gilead Sciences, Inc. announced that the U.S. FDA has approved Epclusa , the first all-oral, pan-genotypic, single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C virus (HCV) infection. Epclusa is also...

Novartis’ midostaurin achieves 60% response rate in advanced systemic mastocytosis

Novartis announced that The New England Journal of Medicine published data for PKC412 demonstrating an overall response rate, defined as a major or partial response, of 60% (95% confidence interval , 49-70%; P<0.001) in patients with advanced systemic mastocytosis...

Merck, Premier Inc collaborate to improve care for osteoporosis patients

Merck and Premier Inc , a leading healthcare improvement company, have agreed to collaborate on the co-development of solutions to help improve population health. Initially, the companies will focus on reducing fracture rates for at-risk osteoporosis patients. ...

Novo Nordisk receives the EMA marketing approval of the mylife YpsoPump insulin pump

Novo Nordisk announces the EMA marketing approval of the mylife(TM) YpsoPump® insulin pump for use with prefilled pump cartridge NovoRapid®PumpCart®. The approval is a key milestone for the collaboration between Novo Nordisk and Ypsomed and their goal to deliver...

Pfizer says Two additional late stage studies of cholesterol drug met goals

Pfizer Inc. announced two additional Phase 3 bococizumab trials, SPIRE-HR and SPIRE-FH , met their primary endpoint, demonstrating a significant reduction in the percent change from baseline in low-density lipoprotein cholesterol (LDL-C) at 12 weeks compared to placebo among...

EU approves Astrazeneca Plc’s New Antibiotic Zavicefta

AstraZeneca announced that the EC has granted marketing authorisation for Zavicefta , a new combination antibiotic for the treatment of patients with serious Gram-negative bacterial infections requiring hospitalisation. The approval includes intravenous use of Zavicefta for...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »